Dr. Twardowski on Sequencing Therapies for Patients With mCRPC

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, medical oncologist, discusses the challenges with sequencing therapies for patients with metastatic castration-resistant prostate cancer (mCRPC).

These questions remain unanswered in the field of prostate cancer, explains Twardowski. There is an advantage in other tumor types, he adds, because there are biomarker-guided therapies.

Experts in prostate cancer do not have much experience in making sequencing decisions, he says. Such choices are often based on clinical criteria and experience. In practice, Twardowski says he uses immunotherapy first as it tends to lay the foundation for future treatments. Additionally, physicians may also start with less toxic therapies and use more toxic options later on.